Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Soo Young, Kim, Seok-Mo, Chang, Hojin, Kim, Bup-Woo, Lee, Yong Sang, Chang, Hang-Seok, Park, Cheong Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581694/
https://www.ncbi.nlm.nih.gov/pubmed/31244783
http://dx.doi.org/10.3389/fendo.2019.00384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581694/
https://www.ncbi.nlm.nih.gov/pubmed/31244783
http://dx.doi.org/10.3389/fendo.2019.00384

Ejemplares similares